Comparative Pharmacology
Head-to-head clinical analysis: OTOCORT versus PREDNISOLONE TEBUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OTOCORT versus PREDNISOLONE TEBUTATE.
OTOCORT vs PREDNISOLONE TEBUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Otocort is a combination product containing hydrocortisone (a corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polymyxin antibiotic). Hydrocortisone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane permeability by binding to lipopolysaccharides.
Corticosteroid that binds to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell activity.
1-2 drops into affected ear(s) twice daily; otic route.
20-60 mg intramuscularly or intra-articularly once daily as a single dose or divided every 6-12 hours; dose varies by indication and severity.
None Documented
None Documented
Hydrocortisone: plasma half-life 1.5-2 hours, biological half-life 8-12 hours due to intracellular receptor binding. Neomycin: terminal half-life 2-4 hours in patients with normal renal function; may prolong to 12-24 hours in renal impairment. Polymyxin B: terminal half-life 6-8 hours in normal renal function; significantly prolonged in renal failure (up to 2-3 days). Clinical context: Topical/otic application yields negligible systemic concentrations, so half-life is relevant only if significant absorption occurs (e.g., damaged tympanic membrane).
Terminal half-life: 2-4 hours (plasma); clinical effects persist longer (18-36 hours) due to prolonged receptor occupancy and transcriptional effects.
Otocort is a combination product containing hydrocortisone, neomycin, and polymyxin B. The corticosteroid component undergoes hepatic metabolism with renal excretion of metabolites (<5% unchanged). Neomycin is minimally absorbed (3-6% from intact skin, higher from wounds) and excreted renally as unchanged drug (30-50%) and metabolites. Polymyxin B is not significantly absorbed through intact skin or tympanic membrane; systemic absorption negligible. Renal excretion of polymyxin B is slow (40-60% over 72 hours) via glomerular filtration. Fecal elimination accounts for <5% of absorbed dose for all components.
Renal: primarily as metabolites, <20% unchanged; small fecal/biliary contribution.
Category C
Category D/X
Otic Antibiotic/Corticosteroid
Corticosteroid